PMID- 34572865
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211001
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 13
IP  - 18
DP  - 2021 Sep 16
TI  - Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted 
      Therapy for Advanced Melanoma: A Nationwide Cohort Study.
LID - 10.3390/cancers13184639 [doi]
LID - 4639
AB  - Recent meta-analyses show conflicting data on sex-dependent benefit following 
      systemic treatment for advanced melanoma patients. We examined the nationwide 
      Dutch Melanoma Treatment Registry (July 2013-July 2018), assessing sex-dependent 
      differences in advanced melanoma patients (stage IIIC/IV) with respect to 
      clinical characteristics, mutational profiles, treatments initiated, grade 3-4 
      adverse events (AEs), treatment responses, and mortality. We included 3985 
      patients, 2363 men (59%) and showed that although men and women with advanced 
      melanoma differ in clinical and tumor characteristics, the safety profile of 
      immune checkpoint inhibition (ICI) is comparable. The data suggest a 10% survival 
      advantage for women, mainly seen in patients >/=60 years of age and patients with 
      BRAF V600 mutant melanoma. Following ICI there was no survival difference.
FAU - van der Kooij, Monique K
AU  - van der Kooij MK
AUID- ORCID: 0000-0002-9764-5467
AD  - Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, 
      P.O. Box 9600, 2300 RC Leiden, The Netherlands.
FAU - Dekkers, Olaf M
AU  - Dekkers OM
AD  - Department of Clinical Epidemiology, Leiden University Medical Center, 
      Albinusdreef 2, P.O. Box 9600, 2300 RC Leiden, The Netherlands.
FAU - Aarts, Maureen J B
AU  - Aarts MJB
AD  - Department of Medical Oncology, Maastricht University Medical Center, P. 
      Debyelaan 25, 6202 AZ Maastricht, The Netherlands.
FAU - van den Berkmortel, Franchette W P J
AU  - van den Berkmortel FWPJ
AD  - Department of Medical Oncology, Zuyderland Medical Center, 6130 MB 
      Sittard-Geleen, The Netherlands.
FAU - Boers-Sonderen, Marye J
AU  - Boers-Sonderen MJ
AD  - Department of Medical Oncology, Radboud University Medical Center, Geert 
      Grooteplein Zuid 10, 6500 HB Nijmegen, The Netherlands.
FAU - de Groot, Jan Willem B
AU  - de Groot JWB
AD  - Isala Oncology Center, Isala, 8000 GK Zwolle, The Netherlands.
FAU - Hospers, Geke A P
AU  - Hospers GAP
AD  - Department of Medical Oncology, University Medical Center Groningen, Hanzeplein 
      1, 9713 GZ Groningen, The Netherlands.
FAU - Piersma, Djura
AU  - Piersma D
AD  - Department of Medical Oncology, Medisch Spectrum Twente, Koningsplein 1, 7512 KZ 
      Enschede, The Netherlands.
FAU - van Rijn, Rozemarijn S
AU  - van Rijn RS
AD  - Department of Medical Oncology, Medical Center Leeuwarden, Henri Dunantweg 2, 
      8934 AD Leeuwarden, The Netherlands.
FAU - Suijkerbuijk, Karijn P M
AU  - Suijkerbuijk KPM
AUID- ORCID: 0000-0003-3604-5430
AD  - Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 
      100, 3584 CX Utrecht, The Netherlands.
FAU - Westgeest, Hans M
AU  - Westgeest HM
AUID- ORCID: 0000-0002-5735-3638
AD  - Department of Internal Medicine, Amphia Ziekenhuis, Molengracht 21, 4818 CK 
      Breda, The Netherlands.
FAU - van der Veldt, Astrid A M
AU  - van der Veldt AAM
AUID- ORCID: 0000-0003-0446-1907
AD  - Departments of Medical Oncology and Radiology & Nuclear Medicine, Erasmus MC 
      Cancer Institute, Dr. Molewaterplein 40, 3000 CA Rotterdam, The Netherlands.
FAU - Vreugdenhil, Gerard
AU  - Vreugdenhil G
AD  - Department of Medical Oncology, Maxima Medical Center, de Run 4600, 5500 MB 
      Veldhoven, The Netherlands.
FAU - Wilgenhof, Sofie
AU  - Wilgenhof S
AD  - Department of Medical Oncology, Netherlands Cancer Institute-Antoni van 
      Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
FAU - Wouters, Michel W J M
AU  - Wouters MWJM
AUID- ORCID: 0000-0001-6173-0662
AD  - Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, 2333 AA Leiden, The 
      Netherlands.
AD  - Department of Surgical Oncology, Netherlands Cancer Institute-Antoni van 
      Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
FAU - Haanen, John B A G
AU  - Haanen JBAG
AD  - Department of Medical Oncology, Netherlands Cancer Institute-Antoni van 
      Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
FAU - van den Eertwegh, Alfonsus J M
AU  - van den Eertwegh AJM
AD  - Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije 
      Universiteit Amsterdam, de Boelelaan 1117, 1081 HZ Amsterdam, The Netherlands.
FAU - Kapiteijn, Ellen
AU  - Kapiteijn E
AUID- ORCID: 0000-0002-4814-6426
AD  - Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, 
      P.O. Box 9600, 2300 RC Leiden, The Netherlands.
LA  - eng
GR  - 836002002/ZONMW_/ZonMw/Netherlands
PT  - Journal Article
DEP - 20210916
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC8465427
OTO - NOTNLM
OT  - advanced melanoma
OT  - immunotherapy
OT  - prospective nation-wide data
OT  - sex
OT  - targeted therapy
COIS- M.J.B.S. has served as an advisory board member for Bristol-Myers Squibb, 
      Novartis, Merck and Pierre Fabre. A.J.M.v.d.E. has served as a speaker for 
      Bristol-Myers Squibb and Novartis and an advisory board member for Bristol Myers 
      Squibb, MSD oncology, Amgen, Roche, Novartis, Sanofi, Pfizer, Ipsen, Merck, 
      Pierre Fabre and has received research grants not related to this paper from 
      Sanofi, Roche, Bristol Myers Squibb, TEVA and Idera. J.W.B.d.G. is a paid 
      consultant for Bristol Myers Squibb, MSD, Pierre Fabre, and Servier. G.A.P.H. is 
      an unpaid consultant/advisory board member for Bristol Myers Squibb, MSD, Roche, 
      and Novartis. D.P. has served as an advisory board member for Amgen, Bristol 
      Myers Squibb and Pierre Fabre. A.A.M.v.d.V. is a paid consultant for Bristol 
      Myers Squibb, MSD, Novartis, Roche, Pfizer, Eisai, Ipsen, Pierre Fabre, Sanofi, 
      and Bayer. J.H. is a paid consultant for AIMM, Neon Therapeutics, Immunocore, 
      Vaximm, and Neogene Therapeutics, and reports receiving commercial research 
      grants from Bristol Myers Squibb, MSD, Novartis, and Neon Therapeutics. K.P.M.S. 
      has served as a consultant and/or advisory board member for Bristol Myers Squibb, 
      Novartis, MSD, Pierre Fabre and AbbVie and received honoraria/research support 
      not related to this manuscript from Novartis, Roche and MSD. All paid to 
      institution. EK has served as a consultant and/or advisory board member for 
      Bristol Myers Squibb, Novartis, Merck, Pierre Fabre and has received research 
      grants not related to this paper from Bristol Myers Squibb. H.M.W. received 
      travel expenses from Ipsen and honoraria from Astellas and Roche. No potential 
      conflicts of interest were disclosed by the other authors. Role of the Funder: 
      The funders had no role in the design of the study; in the collection, analyses 
      or interpretation of data; in the writing of the manuscript, or in the decision 
      to publish the results.
EDAT- 2021/09/29 06:00
MHDA- 2021/09/29 06:01
PMCR- 2021/09/16
CRDT- 2021/09/28 01:07
PHST- 2021/08/19 00:00 [received]
PHST- 2021/09/03 00:00 [revised]
PHST- 2021/09/11 00:00 [accepted]
PHST- 2021/09/28 01:07 [entrez]
PHST- 2021/09/29 06:00 [pubmed]
PHST- 2021/09/29 06:01 [medline]
PHST- 2021/09/16 00:00 [pmc-release]
AID - cancers13184639 [pii]
AID - cancers-13-04639 [pii]
AID - 10.3390/cancers13184639 [doi]
PST - epublish
SO  - Cancers (Basel). 2021 Sep 16;13(18):4639. doi: 10.3390/cancers13184639.